Nicola Little

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Topics

Ulcerative Colitis

Replacement Therapy

Glycemic Control

Randomized Controlled Trial

Top Venues

Hepatology communications

This page only lists publications with an associated author ORCID identifier.

Publications

David E J Jones, Marco Carbone, Invernizzi Pietro, Nicola Little, Frederik Nevens, Mark G Swain, Philippe Wiesel, Cynthia Levy
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology communications 7 (3) (2023)
David E J Jones, Marco Carbone, Invernizzi Pietro, Nicola Little, Frederik Nevens, Mark G Swain, Philippe Wiesel, Cynthia Levy
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology communications 7 (3) (2023)
David E J Jones, Marco Carbone, Invernizzi Pietro, Nicola Little, Frederik Nevens, Mark G Swain, Philippe Wiesel, Cynthia Levy
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology communications 7 (3) (2023)
David E J Jones, Marco Carbone, Invernizzi Pietro, Nicola Little, Frederik Nevens, Mark G Swain, Philippe Wiesel, Cynthia Levy
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology communications 7 (3) (2023)
David E J Jones, Marco Carbone, Invernizzi Pietro, Nicola Little, Frederik Nevens, Mark G Swain, Philippe Wiesel, Cynthia Levy
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology communications 7 (3) (2023)
David E J Jones, Marco Carbone, Invernizzi Pietro, Nicola Little, Frederik Nevens, Mark G Swain, Philippe Wiesel, Cynthia Levy
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology communications 7 (3) (2023)